Abbott Q4 adjusted EPS rises 12% to $1.50; 2026 adjusted EPS outlook $5.55 to $5.80
Abbott reported fourth-quarter 2025 sales of $11.459 billion, up 4.4 percent, and adjusted diluted EPS of $1.50, up 12 percent. GAAP diluted EPS fell to $1.01 from $5.27, mainly because the prior-year quarter included a $7.497 billion non-cash tax benefit. Abbott projects 2026 organic sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80.
Key points
- Full-year 2025 sales were $44.3 billion, up 5.7 percent, and adjusted diluted EPS was $5.15, up 10 percent
- Full-year 2025 GAAP diluted EPS was $3.72, down from $7.64 in 2024, which included a $7.497 billion non-cash tax benefit
- Abbott expects first-quarter 2026 adjusted diluted EPS of $1.12 to $1.18
- The pending Exact Sciences acquisition is expected to close in the second quarter of 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 22, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.